T2 Biosystems, Inc. (0A57.L)
| Chiusura precedente | 0,4049 |
| Aperto | 0,4229 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,4229 - 0,4229 |
| Intervallo di 52 settimane | 0,4229 - 0,4229 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,18 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3050 |
| Prossima data utili | 02 mar 2022 - 07 mar 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results
LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021. Recent Highlights (unaudited) Achieved full year 2021 total revenue of $27.7 million, including product revenue of $16.7 million, representing an increase of 53% and 43%, respectively compared to the prior yearAchieved fourth quarter tot
- GlobeNewswire
T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial
LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initation of a U.S. clinical trial evaluating the performance of its T2Biothreat® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA). The T2Biothreat® Panel, which runs on T2 Biosystems’ T2Dx® Instrument, is a direct-from-blood test panel that provides results in 3-5 hours and simultaneously dete
- GlobeNewswire
T2 Biosystems Announces the Initiation of the T2Resistance® Panel Clinical Trial
LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi-site clinical trial evaluating the performance of its T2Resistance® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA). The T2Resistance® Panel, which runs on T2 Biosystems’ T2Dx® Instrument, is a direct-from-blood test panel that detects 13 antibiotic resistance genes
